• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Establishes New US$200 Million At-The-Market Program

    2/28/25 5:18:00 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email

    Net proceeds expected to be used for corporate purposes including paying down debt, strengthening the Company's cash position, and supporting strategic M&A

    SMITHS FALLS, ON, Feb. 28, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the Company has established a new at-the-market equity program (the "ATM Program") that allows Canopy Growth to issue and sell up to US$200 million (or its Canadian dollar equivalent) of common shares of the Company ("Common Shares") from treasury from time to time in concurrent public offerings in the United States and Canada. Any Common Shares sold in the ATM Program will be sold in transactions made directly on the Nasdaq or the TSX or on any other available U.S. or Canadian trading market for the Common Shares. The volume and timing of sales under the ATM Program, if any, will be determined in the Company's sole discretion and are subject to customary conditions precedent. The Common Shares will be distributed at market prices prevailing at the time of each sale or at certain other prices and, as a result, prices may vary as between purchasers and during the period of distribution under the ATM Program. 

    Canopy Growth Establishes New US$200 Million At-The-Market Program (CNW Group/Canopy Growth Corporation)

    Canopy Growth intends to use the net proceeds from the ATM Program, if any, for investments in businesses and/or to fund any potential future acquisitions and for working capital and general corporate purposes, which may include the repayment of indebtedness, including the optional US$100 million prepayment under the Company's existing credit agreement, which if completed, will automatically extend the maturity date of the Company's term loan to September 18, 2027.

    Sales of Common Shares under the ATM Program will be made pursuant to the terms of an equity distribution agreement dated February 28, 2025 (the "Distribution Agreement") entered into among the Company, BMO Nesbitt Burns Inc., as Canadian agent, and BMO Capital Markets Corp., as U.S. agent (collectively, the "Agents"). The ATM Program will be effective until the earliest of (i) the issuance and sale of all of the Common Shares issuable pursuant to the ATM Program, (ii) the date on which the Company receives notice from a securities regulatory authority that the Canadian Shelf Prospectus and/or Registration Statement (each as defined below) has ceased to be effective, and (iii) July 5, 2026, unless terminated prior to such date by the Company or the Agents in accordance with the terms of the Distribution Agreement. It is expected that the Distribution Agreement will replace the equity distribution agreement dated June 6, 2024 among the Company and the Agents. 

    The offering of Common Shares under the ATM Program is qualified by a prospectus supplement dated February 28, 2025 (the "Canadian Prospectus Supplement") to the Company's Canadian short form base shelf prospectus dated June 5, 2024 (the "Canadian Shelf Prospectus"), each filed with the securities commissions in each of the provinces and territories of Canada, and pursuant to a prospectus supplement dated February 28, 2025 (the "U.S. Prospectus Supplement") to the Company's U.S. base prospectus dated June 5, 2024 (the "U.S. Base Prospectus") included in its registration statement on Form S-3ASR (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "SEC"). The Distribution Agreement, Canadian Prospectus Supplement and Canadian Shelf Prospectus are available on the SEDAR+ website at www.sedarplus.com, and the U.S. Prospectus Supplement, the U.S. Base Prospectus and the Registration Statement are available on EDGAR on the SEC's website at www.sec.gov. Alternatively, these documents may be requested from the Agents by contacting, (i) in Canada: BMO Nesbitt Burns Inc. by mail at Brampton Distribution Centre, 9195 Torbram Road, Brampton, Ontario, L6S 6H2, attn: The Data Group of Companies, by email at [email protected] or by telephone at 905-791-3151 ext. 4312; and (ii) in the United States: BMO Capital Markets Corp. by mail at 151 W 42nd Street, 32nd Floor, New York, NY 10036, attn: Equity Syndicate Department, by email at [email protected], or by telephone at 800-414-3627.

    No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy the Common Shares, nor shall there be any sale of the Common Shares in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

    About Canopy Growth

    Canopy Growth is a world leading cannabis company dedicated to unleashing the power of cannabis to improve lives.

    Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Tweed, 7ACRES, DOJA, Deep Space and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Germany, Poland, and Australia.

    Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA's portfolio includes ownership of Acreage Holdings, a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Brands, a leading North American edibles brand, and majority ownership of Jetty Extracts, a California-based producer of high-quality cannabis extracts and clean vape technology.

    At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer.

    For more information visit www.canopygrowth.com.

    Forward-Looking Statements

    This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the offer and sale of Common Shares under the ATM Program, including the timing and amounts thereof, and the use of any proceeds from the ATM Program, including the optional prepayment under the Company's credit agreement and the maturity date of the Company's term loan.

    Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company's profile on SEDAR+ at www.sedarplus.com and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading "Risk Factors" in the Company's annual report on Form 10-K for the year ended March 31, 2024, its subsequently filed quarterly reports on Form 10-Q and the Canadian Prospectus Supplement, Canadian Shelf Prospectus, U.S. Prospectus Supplement and U.S. Base Prospectus.

    In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/canopy-growth-establishes-new-us200-million-at-the-market-program-302389058.html

    SOURCE Canopy Growth Corporation

    Get the next $CGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    11/10/2025Sell → Hold
    The Benchmark Company
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    2026 Asset Growth: Why Federal Compliance Is the New Metric

    VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using aggressive buyouts as a primary 2026 strategy to secure high-tech efficiency while navigating intense federal scrutiny and capital limits[2]. In this high-stakes environment, companies with a clear and proven path through federal guidelines are capturing the most attention, including Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Canopy Growth (NASDAQ:CGC) (TSX:WEED), Definium Therap

    1/19/26 12:20:49 PM ET
    $CGC
    $DFTX
    $KDP
    Medicinal Chemicals and Botanical Products
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Canopy Growth Announces Strategic Recapitalization Transactions Significantly Strengthening Balance Sheet to Support Growth Strategy

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 Refinances Term Loan due 2027 and Exchanges Convertible Debentures due 2029, Extending Maturities of All Outstanding Indebtedness to Earliest January 2031 While Enhancing Liquidity Profile Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the Company has entered into a series of transactions to recapitalize its balance sheet and extend the ma

    1/8/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc sold $9,951 worth of shares (9,376 units at $1.06), decreasing direct ownership by 1% to 802,992 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    2/12/26 7:53:43 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yanofsky Theresa sold $11,790 worth of shares (10,434 units at $1.13), decreasing direct ownership by 14% to 63,518 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:38:18 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lazzarato David Angelo sold $17,758 worth of shares (15,715 units at $1.13), decreasing direct ownership by 15% to 87,672 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:37:09 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    SEC Filings

    View All

    SEC Form S-3 filed by Canopy Growth Corporation

    S-3 - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 4:15:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 7:05:59 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Canopy Growth Corporation

    10-Q - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 6:45:57 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Canopy Growth with a new price target

    Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

    11/2/22 6:11:10 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada's Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Highly accretive business combination expected to generate significant run-rate synergies of approximately $10 million within 18 months Strengthens Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality, budtender-recommended product portfolio2 MTL's core management team is expected to join Canopy Growth to drive cultivation excellence and enhance the Company's p

    12/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Appoints Tom Stewart as Chief Financial Officer

    Appointment finalizes CFO transition and reinforces Canopy Growth's focus on operational discipline, financial stability, and long-term value creation Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately. Mr. Stewart's appointment supports the continued execution of Canopy Growth's fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progres

    9/17/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

    Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth $298MM cash and cash equivalents, which exceeds debt balances by $70MM at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern have been resolved Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). Al

    11/7/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Report Second Quarter Fiscal 2026 Financial Results on November 7, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2026 ended September 30, 2025 before financial markets open on November 7, 2025. Following the release of its second quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on November 7, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=EEDC9A65-53FA-40BD-9644-D3ABDCF91E72 Replay Information A replay will be accessible by webcast until 11:59 PM ET on February 5, 2026

    10/24/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care